Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture

Martin Wurm, Verena Lubei, Marco Caronna, Martin Hermann, Stefano Buttiglieri, Olaf Bodamer, Adolf Muehl, Ciro Tetta, Raimund Margreiter, Paul Hengster

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The aim of this study was to establish a stand-alone, perfused, rotary cell culture system using small human hepatocytes (SH) for bioartificial liver (BAL) support. SH were grown on cytodex 3 microcarriers (beads) to a maximum density of 1.2 ± 0.3 × 107 cells per mL within 12 days. Size of aggregates formed by up to 15 beads was regulated by rotation speed. Cell function was proven by treatment with ammonia and galactose, and metabolism was analyzed. Treatment strategy was comprised of two phases, namely growth phase and treatment phase. Cells were grown for 6 days and subsequently incubated with ammonia or galactose for 2 days, followed by a 2-day regeneration period and another 2-day treatment phase. Consumption of glucose, release of lactate dehydrogenase, formation of lactate, and production of urea and albumin were determined regularly. Mean galactose consumption was 50 μg per 106 cells per hour, ammonia-induced urea formation was 3.6 μg per 106 cells per hour, and albumin production was 110ng per 106 cells per hour. All metabolic parameters followed a logarithmic trend and were found to be very stable in the second half of the culture period when cells were treated with ammonia or galactose. Dissolved oxygen (%DO), pH, and temperature were monitored in-stream at intervals of 7 min, and the values were logged. Viability and morphology of cells were monitored via confocal microscopy. Viability was around 95% in controls and 90% during treatment. Promising results were obtained in support of our ongoing efforts to establish a fully autonomous BAL support device utilizing SH as a bridge to transplantation.

Original languageEnglish
Pages (from-to)1063-1073
Number of pages11
JournalTissue Engineering - Part A
Volume15
Issue number5
DOIs
StatePublished - May 1 2009

Fingerprint

Artificial Liver
Galactose
Ammonia
Liver
Hepatocytes
Urea
Albumins
Confocal microscopy
Dissolved oxygen
L-Lactate Dehydrogenase
Cell culture
Metabolism
Glucose
Lactic Acid
Confocal Microscopy
Regeneration
Cell Survival
Cell Culture Techniques
Transplantation
Oxygen

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials

Cite this

Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture. / Wurm, Martin; Lubei, Verena; Caronna, Marco; Hermann, Martin; Buttiglieri, Stefano; Bodamer, Olaf; Muehl, Adolf; Tetta, Ciro; Margreiter, Raimund; Hengster, Paul.

In: Tissue Engineering - Part A, Vol. 15, No. 5, 01.05.2009, p. 1063-1073.

Research output: Contribution to journalArticle

Wurm, M, Lubei, V, Caronna, M, Hermann, M, Buttiglieri, S, Bodamer, O, Muehl, A, Tetta, C, Margreiter, R & Hengster, P 2009, 'Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture', Tissue Engineering - Part A, vol. 15, no. 5, pp. 1063-1073. https://doi.org/10.1089/ten.tea.2008.0217
Wurm, Martin ; Lubei, Verena ; Caronna, Marco ; Hermann, Martin ; Buttiglieri, Stefano ; Bodamer, Olaf ; Muehl, Adolf ; Tetta, Ciro ; Margreiter, Raimund ; Hengster, Paul. / Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture. In: Tissue Engineering - Part A. 2009 ; Vol. 15, No. 5. pp. 1063-1073.
@article{6226ca7e5a9d436c84f1a3be08f9a0b1,
title = "Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture",
abstract = "The aim of this study was to establish a stand-alone, perfused, rotary cell culture system using small human hepatocytes (SH) for bioartificial liver (BAL) support. SH were grown on cytodex 3 microcarriers (beads) to a maximum density of 1.2 ± 0.3 × 107 cells per mL within 12 days. Size of aggregates formed by up to 15 beads was regulated by rotation speed. Cell function was proven by treatment with ammonia and galactose, and metabolism was analyzed. Treatment strategy was comprised of two phases, namely growth phase and treatment phase. Cells were grown for 6 days and subsequently incubated with ammonia or galactose for 2 days, followed by a 2-day regeneration period and another 2-day treatment phase. Consumption of glucose, release of lactate dehydrogenase, formation of lactate, and production of urea and albumin were determined regularly. Mean galactose consumption was 50 μg per 106 cells per hour, ammonia-induced urea formation was 3.6 μg per 106 cells per hour, and albumin production was 110ng per 106 cells per hour. All metabolic parameters followed a logarithmic trend and were found to be very stable in the second half of the culture period when cells were treated with ammonia or galactose. Dissolved oxygen ({\%}DO), pH, and temperature were monitored in-stream at intervals of 7 min, and the values were logged. Viability and morphology of cells were monitored via confocal microscopy. Viability was around 95{\%} in controls and 90{\%} during treatment. Promising results were obtained in support of our ongoing efforts to establish a fully autonomous BAL support device utilizing SH as a bridge to transplantation.",
author = "Martin Wurm and Verena Lubei and Marco Caronna and Martin Hermann and Stefano Buttiglieri and Olaf Bodamer and Adolf Muehl and Ciro Tetta and Raimund Margreiter and Paul Hengster",
year = "2009",
month = "5",
day = "1",
doi = "10.1089/ten.tea.2008.0217",
language = "English",
volume = "15",
pages = "1063--1073",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture

AU - Wurm, Martin

AU - Lubei, Verena

AU - Caronna, Marco

AU - Hermann, Martin

AU - Buttiglieri, Stefano

AU - Bodamer, Olaf

AU - Muehl, Adolf

AU - Tetta, Ciro

AU - Margreiter, Raimund

AU - Hengster, Paul

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The aim of this study was to establish a stand-alone, perfused, rotary cell culture system using small human hepatocytes (SH) for bioartificial liver (BAL) support. SH were grown on cytodex 3 microcarriers (beads) to a maximum density of 1.2 ± 0.3 × 107 cells per mL within 12 days. Size of aggregates formed by up to 15 beads was regulated by rotation speed. Cell function was proven by treatment with ammonia and galactose, and metabolism was analyzed. Treatment strategy was comprised of two phases, namely growth phase and treatment phase. Cells were grown for 6 days and subsequently incubated with ammonia or galactose for 2 days, followed by a 2-day regeneration period and another 2-day treatment phase. Consumption of glucose, release of lactate dehydrogenase, formation of lactate, and production of urea and albumin were determined regularly. Mean galactose consumption was 50 μg per 106 cells per hour, ammonia-induced urea formation was 3.6 μg per 106 cells per hour, and albumin production was 110ng per 106 cells per hour. All metabolic parameters followed a logarithmic trend and were found to be very stable in the second half of the culture period when cells were treated with ammonia or galactose. Dissolved oxygen (%DO), pH, and temperature were monitored in-stream at intervals of 7 min, and the values were logged. Viability and morphology of cells were monitored via confocal microscopy. Viability was around 95% in controls and 90% during treatment. Promising results were obtained in support of our ongoing efforts to establish a fully autonomous BAL support device utilizing SH as a bridge to transplantation.

AB - The aim of this study was to establish a stand-alone, perfused, rotary cell culture system using small human hepatocytes (SH) for bioartificial liver (BAL) support. SH were grown on cytodex 3 microcarriers (beads) to a maximum density of 1.2 ± 0.3 × 107 cells per mL within 12 days. Size of aggregates formed by up to 15 beads was regulated by rotation speed. Cell function was proven by treatment with ammonia and galactose, and metabolism was analyzed. Treatment strategy was comprised of two phases, namely growth phase and treatment phase. Cells were grown for 6 days and subsequently incubated with ammonia or galactose for 2 days, followed by a 2-day regeneration period and another 2-day treatment phase. Consumption of glucose, release of lactate dehydrogenase, formation of lactate, and production of urea and albumin were determined regularly. Mean galactose consumption was 50 μg per 106 cells per hour, ammonia-induced urea formation was 3.6 μg per 106 cells per hour, and albumin production was 110ng per 106 cells per hour. All metabolic parameters followed a logarithmic trend and were found to be very stable in the second half of the culture period when cells were treated with ammonia or galactose. Dissolved oxygen (%DO), pH, and temperature were monitored in-stream at intervals of 7 min, and the values were logged. Viability and morphology of cells were monitored via confocal microscopy. Viability was around 95% in controls and 90% during treatment. Promising results were obtained in support of our ongoing efforts to establish a fully autonomous BAL support device utilizing SH as a bridge to transplantation.

UR - http://www.scopus.com/inward/record.url?scp=66249088717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249088717&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2008.0217

DO - 10.1089/ten.tea.2008.0217

M3 - Article

C2 - 18847359

AN - SCOPUS:66249088717

VL - 15

SP - 1063

EP - 1073

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 5

ER -